BioVaxys Technology Corp. — Form D
BioVaxys Technology Corp. of ETOBICOKE, A6, a company, filed a Form D exempt-offering notice with the SEC on 2024-07-12. The offering totals $173K, of which $52K was reported sold. Industry: Biotechnology.
Offering
- Filed: 2024-07-12
- Form: D
- Accession: 0001727689-24-000082
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $173K
- Amount sold: $52K
- Remaining: $121K
- Investors: 1
- Date of first sale: 2024-05-10
- Security types: equity
- Revenue range: No Revenues
- SEC file number: 021-518554
Issuer
- Name: BioVaxys Technology Corp.
- CIK: 0001882559
- Entity type: Corporation
- Jurisdiction: BRITISH COLUMBIA, CANADA
- Incorporated: 2018
- Address: 146 THIRTIETH STREET, SUITE 100, ETOBICOKE, A6, M8W 3D4
- Phone: 646-452-7054
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| Anthony Dutton | Director | Vancouver, A1 |
| Craig Loverock | Director | Etobicoke, A6 |
| James Passin | Director | Vancouver, A1 |
| David Berd | Executive Officer | Etobicoke, A6 |
| Christopher Cherry | Executive Officer | VANCOUVER, A1 |
| Kenneth Kovan | Executive Officer | Etobicoke, A6 |
| James Passin | Executive Officer | Vancouver, A1 |
| David Wang | Director | Los Angeles, CA |
| Lachlan McLeod | Executive Officer | Vancouver, A1 |
| Daren Hermiston | Director | Vancouver, A1 |
Other filings by this issuer (1)
More